

Jalid Sehouli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5250077/publications.pdf>

Version: 2024-02-01

238
papers

6,586
citations

87723

38
h-index

91712

69
g-index

244
all docs

244
docs citations

244
times ranked

8435
citing authors

#	ARTICLE	IF	CITATIONS
1	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	1.2	859
2	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. New England Journal of Medicine, 2019, 380, 822-832.	13.9	373
3	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget, 2016, 7, 1486-1499.	0.8	212
4	The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer, 2018, 18, 476.	1.1	159
5	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine, 2021, 385, 2123-2131.	13.9	144
6	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nature Communications, 2018, 9, 5224.	5.8	116
7	A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. Journal of Clinical Oncology, 2016, 34, 2271-2278.	0.8	114
8	Intraabdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. Journal of Surgical Oncology, 2009, 99, 424-427.	0.8	109
9	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. Gynecologic Oncology, 2013, 128, 15-21.	0.6	107
10	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	1.1	105
11	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 699-709.	5.1	104
12	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	1.4	99
13	Delaying surgery for patients with a previous SARS-CoV-2 infection. British Journal of Surgery, 2020, 107, e601-e602.	0.1	96
14	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.3	96
15	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncology, The, 2018, 19, 1117-1125.	5.1	95
16	Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of Clinical Oncology, 2011, 29, 242-248.	0.8	94
17	Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2017, 23, 2213-2222.	3.2	83
18	MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of Clinical Oncology, 2020, 38, 3753-3762.	0.8	82

#	ARTICLE	IF	CITATIONS
19	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2018, 19, 1247-1258.	5.1	79
20	BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). <i>European Journal of Cancer</i> , 2014, 50, 2090-2098.	1.3	75
21	Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. <i>Anticancer Research</i> , 2004, 24, 1223-9.	0.5	73
22	A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. <i>Annals of Oncology</i> , 2012, 23, 2265-2271.	0.6	72
23	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE). <i>Cancer Medicine</i> , 2021, 10, 208-219.	1.3	69
24	Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1855-1861.	1.2	66
25	Role of tumour-free margin distance for loco-regional control in vulvar cancer – a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study. <i>European Journal of Cancer</i> , 2016, 69, 180-188.	1.3	64
26	The systemic treatment of recurrent ovarian cancer revisited. <i>Annals of Oncology</i> , 2021, 32, 710-725.	0.6	61
27	Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1331-40.	1.2	59
28	Patient Empowerment Improved Perioperative Quality of Care in Cancer Patients Aged ≥ 65 Years – A Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0137824.	1.1	57
29	High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. <i>Oncotarget</i> , 2017, 8, 102912-102922.	0.8	57
30	Characterization of endometriosis-associated immune cell infiltrates (EMaICI). <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 657-664.	0.8	56
31	Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108727.	2.5	53
32	Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2018, 119, 1060-1066.	2.9	47
33	Operative Results after Primary and Secondary Debulking Operations in Advanced Ovarian Cancer (AOC). <i>Journal of Obstetrics and Gynaecology Research</i> , 1998, 24, 447-451.	0.6	46
34	The genetic landscape of 87 ovarian germ cell tumors. <i>Gynecologic Oncology</i> , 2018, 151, 61-68.	0.6	44
35	European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1199-1206.	1.2	44
36	Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109371.	2.5	43

#	ARTICLE	IF	CITATIONS
37	Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration. <i>Journal of Cancer</i> , 2016, 7, 546-554.	1.2	42
38	Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium. <i>Oncotarget</i> , 2017, 8, 106415-106428.	0.8	42
39	Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. <i>Annals of Oncology</i> , 2010, 21, 2201-2205.	0.6	41
40	Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 261.	1.3	41
41	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 415-422.	0.6	38
42	Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. <i>JCI Insight</i> , 2022, 7, .	2.3	36
43	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2020, 87, 102040.	3.4	35
44	European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1097-1100.	1.2	35
45	A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. <i>Annals of Oncology</i> , 2012, 23, 2259-2264.	0.6	34
46	Polymorphism of the IL-8 gene and the risk of ovarian cancer. <i>Cytokine</i> , 2015, 71, 334-338.	1.4	33
47	Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patientsâ€™ Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 243-253.	0.4	33
48	Vulvar cancer in Germany: increase in incidence and change in tumour biological characteristics from 1974 to 2013. <i>Acta OncolÃ³gica</i> , 2018, 57, 324-330.	0.8	33
49	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). <i>Annals of Oncology</i> , 2016, 27, 2236-2241.	0.6	32
50	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	3.0	32
51	A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7621-7632.	3.2	31
52	Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 243-250.	1.1	30
53	Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapyâ€™Innovative Models Prolong Survival (OCTIPS) Consortium. <i>European Journal of Cancer</i> , 2017, 79, 214-225.	1.3	29
54	A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. <i>Annals of Oncology</i> , 2002, 13, 1749-1755.	0.6	28

#	ARTICLE	IF	CITATIONS
55	First-Line Chemotherapy with Weekly Paclitaxel and Carboplatin for Advanced Ovarian Cancer: A Phase I Study. <i>Gynecologic Oncology</i> , 2002, 85, 321-326.	0.6	28
56	Current role and future aspects of topotecan in relapsed ovarian cancer. <i>Current Medical Research and Opinion</i> , 2009, 25, 639-651.	0.9	28
57	Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma. <i>PLoS ONE</i> , 2015, 10, e0116977.	1.1	28
58	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. <i>Annals of Oncology</i> , 2016, 27, 1733-1739.	0.6	28
59	Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors. <i>JAMA Oncology</i> , 2020, 6, 1923.	3.4	27
60	Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 585-591.	1.1	26
61	Wilms tumor protein 1 (WT1) – Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 140, 494-502.	0.6	26
62	OVQUEST – Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2019, 155, 126-134.	0.6	26
63	Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism. <i>British Journal of Cancer</i> , 2018, 119, 847-854.	2.9	24
64	The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 521-528.	1.0	24
65	Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. <i>Human Pathology</i> , 2019, 85, 299-308.	1.1	24
66	Effects of sarcopenia and malnutrition on morbidity and mortality in gynecologic cancer surgery: results of a prospective study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 393-402.	2.9	24
67	When and how should peritoneal endometriosis be operated on in order to improve fertility rates and symptoms? The experience and outcomes of nearly 100 cases. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 143-155.	0.8	24
68	The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients – results from the OVCAD study. <i>Tumor Biology</i> , 2016, 37, 3009-3016.	0.8	23
69	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2018, 20, 280-288.	2.3	23
70	Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer – A Study of the GANNET53 Consortium. <i>Frontiers in Oncology</i> , 2019, 9, 832.	1.3	23
71	Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. <i>Annals of Oncology</i> , 2012, 23, 556-562.	0.6	22
72	Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer – a study by the OVCAD consortium. <i>Gynecologic Oncology</i> , 2013, 128, 38-43.	0.6	22

#	ARTICLE	IF	CITATIONS
73	Systematic pelvic and paraaortic lymphadenectomy in early high-risk or advanced endometrial cancer. Archives of Gynecology and Obstetrics, 2015, 292, 1321-1327.	0.8	22
74	Symptomization and triggering processes: Ovarian cancer patients' narratives on pre-diagnostic sensation experiences and the initiation of healthcare seeking. Social Science and Medicine, 2014, 119, 123-130.	1.8	21
75	The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2018, 150, 151-157.	0.6	21
76	Nerve-sparing radical hysterectomy: steps to standardize surgical technique. International Journal of Gynecological Cancer, 2019, 29, 1203-1208.	1.2	21
77	Expression III: patients'™ expectations and preferences regarding physician's patient relationship and clinical management" results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Annals of Oncology, 2018, 29, 910-916.	0.6	20
78	Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. Gynecologic Oncology, 2019, 153, 286-291.	0.6	20
79	Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study. Gynecologic Oncology, 2021, 161, 396-401.	0.6	20
80	Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer. Annals of Oncology, 2003, 14, 1501-1504.	0.6	19
81	AID/APOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer. BMC Genomics, 2016, 17, 643.	1.2	19
82	Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian Cancer. Computational and Structural Biotechnology Journal, 2019, 17, 537-560.	1.9	19
83	Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Research, 2003, 23, 1115-8.	0.5	19
84	Neurogenic Inflammation in the Context of Endometriosis" What Do We Know?. International Journal of Molecular Sciences, 2021, 22, 13102.	1.8	19
85	HIF1 α ; is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer – a study of the OVCAD Consortium. OncoTargets and Therapy, 2014, 7, 1563.	1.0	18
86	Cytoreductive surgery for ovarian cancer: quality assessment. Annals of Oncology, 2017, 28, viii25-viii29.	0.6	18
87	Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer. Scientific Reports, 2018, 8, 13483.	1.6	18
88	A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecologic Oncology, 2012, 124, 205-209.	0.6	17
89	Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. Anticancer Research, 2014, 34, 6725-30.	0.5	17
90	Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer. Annals of Surgical Oncology, 2012, 19, 1326-1333.	0.7	16

#	ARTICLE	IF	CITATIONS
91	Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium. <i>Tumor Biology</i> , 2016, 37, 12329-12337.	0.8	16
92	A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 541-550.	1.2	16
93	A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 191-199.	0.8	16
94	Lipid reprogramming induced by the TFEB-ERR α axis enhanced membrane fluidity to promote EC progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 28.	3.5	16
95	New aspects of adjuvant therapy in endometrial cancer: Current standards and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 204-212.	2.0	15
96	Predicting the course of disease in recurrent vulvar cancer – A subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2019, 154, 571-576.	0.6	15
97	Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. <i>Gynecologic Oncology</i> , 2019, 154, 539-546.	0.6	15
98	Review of gemcitabine-based combinations for platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 23-30.	1.2	14
99	Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1063-1073.	1.2	14
100	Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 498-503.	1.2	14
101	Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: A metaanalysis of four prospective randomised phase III trials with 5114 patients. <i>European Journal of Cancer</i> , 2015, 51, 825-832.	1.3	13
102	Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. <i>Oncotarget</i> , 2016, 7, 15648-15661.	0.8	13
103	Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery. <i>Transfusion</i> , 2018, 58, 1870-1880.	0.8	13
104	Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).. <i>British Journal of Cancer</i> , 2018, 119, 330-338.	2.9	13
105	Transfusion of red blood cells does not impact progression-free and overall survival after surgery for ovarian cancer. <i>Transfusion</i> , 2019, 59, 3589-3600.	0.8	13
106	Mesothelin as a target for cervical cancer therapy. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 211-216.	0.8	13
107	Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 62-66.	1.2	13
108	A Concise Paradigm on Radical Hysterectomy: The Comprehensive Anatomy of Parametrium, Paracolpium and the Pelvic Autonomic Nerve System and Its Surgical Implication. <i>Cancers</i> , 2020, 12, 1839.	1.7	13

#	ARTICLE	IF	CITATIONS
109	Plasma calcitonin gene-related peptide (CGRP) in migraine and endometriosis during the menstrual cycle. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1251-1259.	1.7	13
110	ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN trial). <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1323-1333.	0.8	13
111	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1508-1529.	1.2	13
112	PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. <i>Anticancer Research</i> , 2015, 35, 6329-34.	0.5	13
113	In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging. <i>Cancers</i> , 2022, 14, 1021.	1.7	13
114	Regional hyperthermia of the abdomen, a pilot study towards the treatment of peritoneal carcinomatosis. <i>Radiation Oncology</i> , 2015, 10, 157.	1.2	12
115	Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging. <i>Anticancer Research</i> , 2018, 38, 4813-4817.	0.5	12
116	Dilution of Molecular Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 213-219.	3.2	12
117	Favorable therapeutic response after anti-Mesothelin antibody drug conjugate treatment requires high expression of Mesothelin in tumor cells. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1255-1262.	0.8	12
118	EZH2 Loss Drives Resistance to Carboplatin and Paclitaxel in Serous Ovarian Cancers Expressing ATM. <i>Molecular Cancer Research</i> , 2020, 18, 278-286.	1.5	12
119	The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study. , 2017, 37, 5609-5616.		12
120	Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor \pm in high-grade serous ovarian carcinoma. <i>Human Pathology</i> , 2017, 67, 30-36.	1.1	11
121	Prevention of palmo-plantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®). <i>Supportive Care in Cancer</i> , 2017, 25, 3545-3549.	1.0	11
122	Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients A study of the OVCAD consortium. <i>Gynecologic Oncology</i> , 2018, 149, 371-380.	0.6	11
123	Possible Role of the Posterior Compartment Peritonectomy, as a Part of the Complex Surgery, Regarding Recurrence Rate, Improvement of Symptoms and Fertility Rate in Patients with Endometriosis, Long-Term Follow-Up. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 1103-1111.	0.3	11
124	Role of predictive markers for severe postoperative complications in gynecological cancer surgery: a prospective study (RISC-Gyn Trial). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1975-1982.	1.2	11
125	Sexually assaulted women: Results of a retrospective analysis of 850 women in Germany. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 250, 117-123.	0.5	11
126	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1997-2001.	1.2	11

#	ARTICLE	IF	CITATIONS
127	Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1791-1802.	1.3	11
128	Functional changes of immune cells: signal of immune tolerance of the ectopic lesions in endometriosis?. <i>Reproductive BioMedicine Online</i> , 2021, 43, 319-328.	1.1	11
129	A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 861-868.	1.1	10
130	Dual targeting of estrogen receptor α and estrogen-related receptor α : a novel endocrine therapy for endometrial cancer. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6757-6767.	1.0	10
131	Preoperative quality of life as prediction for severe postoperative complications in gynecological cancer surgery: results of a prospective study. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 1057-1063.	0.8	10
132	The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 2613.	1.7	10
133	Total retroperitoneal en bloc resection of multivisceral-peritoneal packet (TROMP operation): a novel surgical technique for advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 648-653.	1.2	10
134	Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death. <i>Current Oncology</i> , 2022, 29, 2808-2822.	0.9	10
135	A new therapeutical approach: Topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. <i>Journal of Obstetrics and Gynaecology Research</i> , 2003, 29, 123-131.	0.6	9
136	Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. <i>British Journal of Cancer</i> , 2014, 111, 1519-1525.	2.9	9
137	Predictive and Prognostic Value of sPRR in Patients with Primary Epithelial Ovarian Cancer. <i>Analytical Cellular Pathology</i> , 2016, 2016, 1-6.	0.7	9
138	Preference of elderly patients to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. <i>Gynecologic Oncology Research and Practice</i> , 2017, 4, 6.	3.6	9
139	Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1185-1195.	1.2	9
140	Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells. <i>Oncotarget</i> , 2018, 9, 12682-12694.	0.8	9
141	Participation of elderly gynecological cancer patients in clinical trials. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 797-804.	0.8	9
142	The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2018, 38, 3619-3625.	0.5	9
143	Impact of brief prewarming on anesthesia-related core-temperature drop, hemodynamics, microperfusion and postoperative ventilation in cytoreductive surgery of ovarian cancer: a randomized trial. <i>BMC Anesthesiology</i> , 2019, 19, 161.	0.7	9
144	Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 509-514.	1.2	9

#	ARTICLE	IF	CITATIONS
145	Biological Impact of Unilateral Oophorectomy: Does the Number of Ovaries Really Matter?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 331-338.	0.8	9
146	New associate Editor Prof. Dr. J. Sehouli for the section Gynecologic Oncology. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1-1.	0.8	8
147	Key regulator of cellular metabolism, estrogen-related receptor α , a new therapeutic target in endocrine-related gynecological tumor. <i>Cancer Management and Research</i> , 2018, Volume 10, 6887-6895.	0.9	8
148	Can Fried Frailty Score predict postoperative morbidity and mortality in gynecologic cancer surgery? Results of a prospective study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 428-433.	0.5	8
149	Adequate Utilization of Emergency Services in Germany: Is There a Differential by Migration Background?. <i>Frontiers in Public Health</i> , 2020, 8, 613250.	1.3	8
150	Sexual, bladder and bowel function following different minimally invasive techniques of radical hysterectomy in patients with early-stage cervical cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 2335-2343.	1.2	8
151	Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1205-8.	1.1	8
152	Pain Mechanisms in Peritoneal Diseases Might Be Partially Regulated by Estrogen. <i>Reproductive Sciences</i> , 2018, 25, 424-434.	1.1	7
153	LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1548-1553.	1.2	7
154	Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 49.	1.3	7
155	Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 713-720.	1.2	7
156	A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer. <i>Cancers</i> , 2021, 13, 1764.	1.7	7
157	Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines – A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. <i>Viruses</i> , 2021, 13, 2290.	1.5	7
158	Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. <i>ESMO Open</i> , 2022, 7, 100311.	2.0	7
159	Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study. <i>Anticancer Research</i> , 2015, 35, 6869-75.	0.5	7
160	Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum. <i>Oncology Research and Treatment</i> , 2004, 27, 58-64.	0.8	6
161	Unmet family planning needs among female refugees and asylum seekers in Germany – is free access to family planning services enough? Results of a cross-sectional study. <i>Reproductive Health</i> , 2020, 17, 115.	1.2	6
162	Post-operative management and follow-up of surgical treatment in the case of rectovaginal and retrocervical endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 957-967.	0.8	6

#	ARTICLE	IF	CITATIONS
163	Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 963-968.	0.8	6
164	New <i>in vitro</i> system to predict chemotherapeutic efficacy of drug combinations in fresh tumor samples. <i>PeerJ</i> , 2017, 5, e3030.	0.9	6
165	Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test). <i>Journal of Ovarian Research</i> , 2017, 10, 72.	1.3	5
166	Risk factors for 30-day complications after cancer surgery in geriatric patients: a secondary analysis. <i>Acta Anaesthesiologica Scandinavica</i> , 2018, 62, 451-463.	0.7	5
167	Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 842.	1.6	5
168	Anxiety of myoma patients: results of standardized interviews with the State Trait Anxiety Inventory and the Kessler 10 questionnaire. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2020, 41, 122-130.	1.1	5
169	Secondary malignancies in long-term ovarian cancer survivors: results of the "Carolin meets HANNA" study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 709-712.	1.2	5
170	Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients. <i>ESMO Open</i> , 2021, 6, 100081.	2.0	5
171	Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. <i>Cancers</i> , 2021, 13, 3777.	1.7	5
172	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e37.	1.0	5
173	Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). <i>Journal of Clinical Oncology</i> , 2007, 25, 5526-5526.	0.8	5
174	Panitumumab in platinum-sensitive epithelial ovarian cancer patients with KRAS wild-type: The PROVE-study, a phase II randomized multicenter study of the North-Eastern German Society of Gynaecological Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 5558-5558.	0.8	5
175	What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. <i>Journal of Clinical Oncology</i> , 2017, 35, e17096-e17096.	0.8	5
176	Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 5567-5567.	0.8	5
177	ERR β acts as a potential agonist of PPAR γ to induce cell apoptosis and inhibit cell proliferation in endometrial cancer. <i>Aging</i> , 2020, 12, 23029-23046.	1.4	5
178	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. <i>Cancers</i> , 2022, 14, 168.	1.7	5
179	Current practice and physicians' opinion about preoperative hair removal as a part of ERAS pathway implementation in gynecology and gynecology-oncology: a NOGGO-AGO survey of 148 gynecological departments in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1607-1618.	0.8	4
180	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1603-1607.	1.2	4

#	ARTICLE	IF	CITATIONS
181	The role of acculturation in migrants' use of gynecologic emergency departments. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 149, 24-30.	1.0	4
182	Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HR-QoL) in Patients with Ovarian Cancer: What Is Different Compared to Healthy Women?. <i>Cancers</i> , 2021, 13, 631.	1.7	4
183	Results of a German wide survey towards current surgical approach in early stage cervical cancer NOGGO MONITOR 11. <i>Scientific Reports</i> , 2021, 11, 9774.	1.6	4
184	Age, treatment and prognosis of patients with squamous cell vulvar cancer (VSCC) - analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2021, 161, 442-448.	0.6	4
185	Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 465-472.	0.6	4
186	Prognostic significance of epithelial cells in the blood of patients with gynaecological malignancies. <i>Anticancer Research</i> , 2003, 23, 4133-40.	0.5	4
187	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. <i>Cancers</i> , 2022, 14, 1780.	1.7	4
188	Endometriosis-associated Pain in Patients with and without Hormone Therapy. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2017, 9, 200-205.	0.3	3
189	Nerve-Sparing Systematic Lymph Node Dissection in Gynaecological Oncology: An Innovative Neuro-Anatomical and Surgical Protocol for Enhanced Functional Outcomes. <i>Cancers</i> , 2020, 12, 3473.	1.7	3
190	Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2020, , jmedgenet-2020-107353.	1.5	3
191	Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1267-1274.	0.8	3
192	Gynecologic oncology on the global health agenda: A wake-up call. <i>Gynecologic Oncology</i> , 2021, 161, 336-338.	0.6	3
193	Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 1143.	1.3	3
194	Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily pretreated patients with relapsed ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 5072-5072.	0.8	3
195	Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 920-926.	1.2	3
196	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancer—A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 5865.	1.7	3
197	Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer. <i>PLoS ONE</i> , 2022, 17, e0262770.	1.1	3
198	Detection of epithelial carcinoma cells in the blood of patients with gynaecological malignancies. <i>Anticancer Research</i> , 2003, 23, 1093-7.	0.5	3

#	ARTICLE	IF	CITATIONS
199	Use of paclitaxel for advanced ovarian cancer in clinical practice: analysis of 541 patients. Results from a German multi-centre observational study. <i>Anticancer Research</i> , 2010, 30, 4245-50.	0.5	3
200	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	1.7	3
201	Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003334.	1.2	3
202	Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 716-723.	1.2	3
203	Discussion: session 1. <i>Future Oncology</i> , 2013, 9, 25-27.	1.1	2
204	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 143-151.	1.4	2
205	Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 154-159.	0.5	2
206	Evaluation of Biomarkers in Myoma Patients: A Prospective Study Investigating the Role of LDH, CA 125, and IGF-1 after Uterus-Preserving Surgical Therapy. <i>Gynecologic and Obstetric Investigation</i> , 2021, 86, 100-107.	0.7	2
207	EUS-guided Transgastric Drainage to Manage a Postoperative Pancreatic Fistula After Distal Pancreatectomy and Splenectomy in Recurrent Ovarian Cancer: A Case Report. <i>Anticancer Research</i> , 2021, 41, 3649-3656.	0.5	2
208	Bevacizumab Combined with Platinumâ€“Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients. <i>Cancers</i> , 2021, 13, 4739.	1.7	2
209	Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 98-103.	1.2	2
210	The impact of preoperative malnutrition on surgery outcome and overall survival in ovarian or peritoneal cancer patients: A prospective study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5574-5574.	0.8	2
211	Sentinel Lymph Node Staging with Indocyanine Green for Patients with Cervical Cancer: The Safety and Feasibility of Open Approach Using SPY-PHI Technique. <i>Journal of Clinical Medicine</i> , 2021, 10, 4849.	1.0	2
212	Reconstructive Surgery versus Primary Closure following Vulvar Cancer Excision: A Wide Single-Center Experience. <i>Cancers</i> , 2022, 14, 1695.	1.7	2
213	Ten years of live surgical broadcast at CharitÃ©-MAYO conferences (2010â€“2019): a systematic evaluation of the surgical outcome. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003173.	1.2	2
214	Quality assurance and improvement in oncology using guideline-derived quality indicators â€“ results of gynaecological cancer centres certified by the German cancer society (DKG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1703-1715.	1.2	2
215	Patientsâ€™ perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of lifeâ€“a study of the North-Eastern-German Society of Gynecological Oncology. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1385-1389.	0.8	1
216	Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma. <i>Pharmaceutical Research</i> , 2019, 36, 7.	1.7	1

#	ARTICLE	IF	CITATIONS
217	Survival outcomes of women with grade 3 endometrioid endometrial cancer: the impact of adjuvant treatment strategies. Archives of Gynecology and Obstetrics, 2021, , 1.	0.8	1
218	Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily pretreated patients with relapsed ovarian cancer. Journal of Clinical Oncology, 2004, 22, 5072-5072.	0.8	1
219	Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer. Journal of Clinical Oncology, 2004, 22, 5139-5139.	0.8	1
220	186â€¦Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma-analysis of 7 phase III trials by AGO Studygroup + ENGOT. , 2021, , .		1
221	Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO). Journal of Clinical Oncology, 2009, 27, 5553-5553.	0.8	1
222	Impact of COVID-19 on gynaecological patient care: results of patientâ€™s survey with 327 patients. Archives of Gynecology and Obstetrics, 2022, 305, 389-395.	0.8	1
223	Gemcitabine in Recurrent Ovarian Cancer. American Journal of Cancer, 2005, 4, 345-346.	0.4	0
224	Conclusion. Future Oncology, 2013, 9, 41-41.	1.1	0
225	Patientsâ€™ subjective assessment as a decisive predictor of malignancy in pelvic masses: results of a multicentric, prospective pelvic mass study. Journal of Psychosomatic Obstetrics and Gynaecology, 2020, , 1-6.	1.1	0
226	Tumour biology in advanced ovarian cancer: Do older patients (>65 years) have other tumour characteristics than younger patients?. Journal of Clinical Oncology, 2004, 22, 5137-5137.	0.8	0
227	Randomized Phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer. Journal of Clinical Oncology, 2004, 22, 5139-5139.	0.8	0
228	Final analysis of weekly paclitaxel and weekly carboplatin (P) as first-line chemotherapy in 130 patients with advanced ovarian cancer (AOC). Journal of Clinical Oncology, 2005, 23, 5057-5057.	0.8	0
229	Current management of borderline ovarian tumors: A multicenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO). Journal of Clinical Oncology, 2009, 27, e16568-e16568.	0.8	0
230	Do patients with recurrent ovarian cancer benefit from relative tumor reduction? Results from a prospective study. Journal of Clinical Oncology, 2009, 27, e16541-e16541.	0.8	0
231	Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.. Journal of Clinical Oncology, 2015, 33, 5552-5552.	0.8	0
232	First results of Expression V Study, a survey by the North-Eastern-German Society of Gynaecological Oncology (NOGGO), assessing the therapy expectations of breast and ovarian cancer patients with different ethnicity in Germany.. Journal of Clinical Oncology, 2015, 33, e16582-e16582.	0.8	0
233	Adequate utilisation of emergency services in Germany: a differential by migration background?. European Journal of Public Health, 2019, 29, .	0.1	0
234	Progress of evidence-based treatment decision support utilizing Molecular Health Guide in patients with gynecological solid tumors over three to six years. , 2020, 80, .		0

#	ARTICLE	IF	CITATIONS
235	Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. <i>Cancers</i> , 2022, 14, 418.	1.7	0
236	Safety, tolerability and activity of gefitinib (ZD1839) in combination with tamoxifen in ovarian cancer patients refractory to platinum-taxane based therapy – a Phase-II study of the Ovarian Cancer Study Group (AGO Ovar 2.6). <i>Journal of Clinical Oncology</i> , 2004, 22, 5016-5016.	0.8	0
237	Tumour biology in advanced ovarian cancer: Do older patients (>65 years) have other tumour characteristics than younger patients?. <i>Journal of Clinical Oncology</i> , 2004, 22, 5137-5137.	0.8	0
238	ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5617-TPS5617.	0.8	0